FTSE MIB
34.492,41 +44,84 (+0,13%) Dow Jones
38.686,32 +574,84 (+1,51%) Nasdaq
16.735,02 -2,06 (-0,01%) Nikkei 225
38.487,90 +433,77 (+1,14%) Petrolio
77,18 -0,73 (-0,94%) Bitcoin EUR
62.327,70 -794,14 (-1,26%)
MaxCyte, Inc. (MXCT)
Dopo ore:
| Chiusura precedente | 4,6500 |
| Aperto | 4,5600 |
| Denaro | 4,4300 x 100 |
| Domanda | 4,4900 x 400 |
| Min-Max giorno | 4,3800 - 4,7250 |
| Intervallo di 52 settimane | 2,4500 - 5,5450 |
| Volume | |
| Media Volume | 548.147 |
| Capitalizzazione | 491,684M |
| Beta (mensile su 5 anni) | 1,07 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,3500 |
| Prossima data utili | 07 ago 2024 - 12 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 9,25 |
GlobeNewswireMaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance
ROCKVILLE, Md., Oct. 04, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing, today announced preliminary revenue for the third quarter ended September 30, 2023 and updated its full year 2023 revenue guidance. Preliminary Third Quarter 2023 Revenue Total revenue of $7.8 – 8
- GlobeNewswire
MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing
ROCKVILLE, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announced the appointment of Ali Soleymannezhad as Executive Vice President of Bioprocessing, effective August 21, 2023. Mr. Soleymannezhad will lead global product
- GlobeNewswire
MaxCyte to Participate in Baird Global Healthcare Conference
ROCKVILLE, Md., Sept. 05, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced Company management will participate at the Baird Global Healthcare Conference on Wednesday, September 13th at 2:35 p.m. Eastern Time. A live and archived webcast
